AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05324553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional
Study NCT05324553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal Swab
Description: Buccal swab may be requested, if necessary, to generate germline data.
Study NCT06150430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APO
Description: Subjects will take part in 14 experimental sessions: two baseline sessions (T1-T2), three familiarization sessions (F1-F3), six training sessions (E1-E6), two assessment sessions (one pre-training T3 and one post training T4) and one 2-month follow-up session (T5). Depending on the session, the subject will walk with and/or without the APO. During the assessment sessions (T3-T4), the subject will be evaluated through different standard tests (such as 10MWTs and 2mWTs) and instrumented gait analysis, with and without the APO.~The goal of each training session (E1-E6) will be to achieve a minimum of 30 minutes of overground walking assisted by the APO, leaving up to 15 minutes to rest if needed. Training sessions will occur 2-3 times a week for 2-3 weeks to complete the training protocol.
Study NCT04770350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
Study NCT06208033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMET12
Description: 1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1,Pemetrexed Disodium AUV＝5 d1,Q3W;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；
Study NCT06208033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMET12
Description: 1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, 3 weeks for one cycle.cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1，d8，d15;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；
Study NCT06208033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMET12
Description: 1. chemotherapy：Docetaxel 60-75 mg/m2 d1, administrated for 2-4 cycles, 3 weeks for one cycle.~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；
Study NCT06213272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phono-Motor Therapy
Description: The goal of PMT is to build orthographic and phonological awareness and phonological sequence knowledge. During PMT, participants will complete a series of tasks manipulating minimal sound units (consonants (C) \& vowels (V)), combining these units into syllables (CVC, CVCC, CCVC) and syllable sequences (real words and readable nonwords). PMT will aim to engage 5 modalities: visual, acoustic, tactile kinesthetic, motor, and orthographic. Multisyllabic stimuli used during treatment will consist of 40 real words and 68 readable nonword letter strings.
Study NCT05540405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-dose bitter melon
Description: Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)
Study NCT05540405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-dose bitter melon
Description: Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
Study NCT06213272 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phono-Motor Therapy
Description: The goal of PMT is to build orthographic and phonological awareness and phonological sequence knowledge. During PMT, participants will complete a series of tasks manipulating minimal sound units (consonants (C) \& vowels (V)), combining these units into syllables (CVC, CVCC, CCVC) and syllable sequences (real words and readable nonwords). PMT will aim to engage 5 modalities: visual, acoustic, tactile kinesthetic, motor, and orthographic. Multisyllabic stimuli used during treatment will consist of 40 real words and 68 readable nonword letter strings.
Study NCT05540405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will receive 2 placebo capsules/d (300 mg each)
Study NCT06213272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET)
Description: Stationary ergometer cycling at 60% heart rate range for 20 minutes, plus 5 minutes of warm up and cool down.
Study NCT06213272 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Light stretching activities targeting the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot.
Study NCT06304610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire to probe socio-demographic data and information regarding sexual and reproductive health.
Study NCT06304610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPV self-sample
Description: Collection of HPV self-sample. The study nurse will explain step by step how the participant should take the test. The participant will also be given written instructions and the study nurse will always be around if the participant has any questions. The participant will be asked to take the self-sample in a private room with toilet. After collection the sample is handed back to the study nurse, who will then take the samples to the laboratory for analysis.
Study NCT06304610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endocervical sample
Description: Endocervical sample taken by the gynaecologist. This procedure can be somewhat uncomfortable but not painful. The participant may always ask questions if she has any doubts or questions. The gynaecologist will perform the standard colposcopy examination after collection (for which the woman sits in the colposcopy waiting room)
Study NCT04888689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actimyo°
Description: Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
Study NCT04888689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMU
Description: IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope.~These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes.
Study NCT04938492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for loneliness (CBT-L)
Description: 6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use.
Study NCT04938492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Health Education Training (PHET)
Description: Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
Study NCT05546268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral MRT-2359
Description: Orally administered tablets of MRT-2359.
Study NCT05546268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral MRT-2359
Description: Orally administered tablets of MRT-2359 in conjunction with intramuscular administration of fulvestrant.
Study NCT05546268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral MRT-2359
Description: Orally administered tablets of MRT-2359 in conjunction with orally administered enzalutamide.
Study NCT04659863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
Study NCT04659863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% sodium chloride in water for injection) for subcutaneous injection
Study NCT04770571 — intervention group
Intervention type: DEVICE
Intervention: observational study
Description: observational
Study NCT06193174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C134 Re-Administration
Description: Administration of a second dose of C134 to participants that have completed the study Trial of C134 in Patients With Recurrent GBM (C134-HSV-1).
Study NCT06349408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI3001
Description: The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.~IBI3001 is proposed to be administered by intravenous infusion (IV)
Study NCT04770584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear Conditioning
Description: Participants will be administered increasing intensities of mild electric shock via electrodes connected to the foot. New Biopac stimulators that can deliver higher shock intensity, provided participants agreement will be used to assure adequate conditioning levels. Stimulation is measures in milliamps (mA), and each delivered stimulation will be 0.5 seconds long (500 milliseconds). To colored (blue, red, \& yellow) light stimuli (CS). The light stimulus is followed by a shock or no shock depending on color.
Study NCT04770584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avoidance conditioning
Description: Via button pressing. Only one stimulus-CS will enable control over experiencing the shock: the participant can press the button during the first 2 seconds of the light presentation to avoid the shock.
Study NCT04770584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pavlovian fear extinction learning
Description: After avoidance conditioning, the CS+ associated with avoidance responding appears with no button to press and no shock is administered.
Study NCT04770584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Willingness to pay to avoid shock
Description: On the next day, participants receive a monetary stipend to use to pay to guarantee that they are not to receive any shocks if they press a button from the CS+. This and all previously described experimental phases noted above will occur inside of the fMRI scanner.
Study NCT06215027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: Dance protocol
Study NCT05867433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STHS Intervention
Description: STHS program~The intervention group (10 schools) will participate in the STHS program. During the fall semester (September to December), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that provide education on civic engagement, healthy eating, and physical activity. During the spring semester (February to May), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that focus on implementing the school health environmental change project and receive support for maintaining individual-level healthy eating and physical activity behaviors.
Study NCT05559931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: IV infusion over 6 hours
Study NCT05559931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion over 6 hours
Study NCT05921344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection
Description: Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
Study NCT05739643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FBX-101
Description: A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
Study NCT05867433 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: No STHS program~The usual care group will be offered the same activities as the intervention group after the conclusion of the research study.
Study NCT05592626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR0602
Description: solution, intravenous infusion
Study NCT05647915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine plus lifestyle intervention
Description: berberine hydrochloride 500mg twice a day for 6 months plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc.
Study NCT05647915 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus lifestyle intervention
Description: Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc.
Study NCT06492707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decoy-resistant interleukin-18
Description: Given SC
Study NCT06492707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06492707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT05949645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apreo Implant Group
Description: One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
Study NCT06264635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich-Plasma
Description: PRP refers to a treatment where a patient's own blood is used to promote healing. Blood is drawn, processed to concentrate the platelets, and then re-injected into the injured area to stimulate tissue repair.
Study NCT06264635 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Provider will go through the same motions as injecting PRP, but will use saline instead which has no known effect.
Study NCT06526195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS HF System
Description: The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
Study NCT06526195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate 3 Left Ventricular Assist System
Description: The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.
Study NCT06526195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline Medical Directed Therapy
Description: Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
Study NCT05805137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WoundWatch® wound monitoring system
Description: eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch® system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
Study NCT05714085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat tablet
Description: 2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form
Study NCT05714085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat suspension
Description: 0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form
Study NCT05714085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo for vericiguat administered orally once daily in tablet form
Study NCT05714085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suspension
Description: Placebo for vericiguat administered orally once daily in suspension form
Study NCT04857164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab combined with Chemotherapy
Description: Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer Chemotherapy regimen is selected by the investigator immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
Study NCT04979806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime-zidebactam (FEP-ZID)
Description: 3 g (2 g FEP + 1 g ZID) IV q8h
Study NCT04979806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 1 g IV q8h
Study NCT05938478 — intervention group
Intervention type: DRUG
Intervention: Tralokinumab
Description: This is a prospective observational cohort study. There is no treatment allocation. Participants that have been exposed to tralokinumab before enrollment into the study will be enrolled.
Study NCT05703074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nicotinamide Riboside (NR)
Description: 4 capsules (a total of 1000 mg) 2 times daily for 84 days
Study NCT05703074 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mind-body reprocessing therapy (MBRT)
Description: 4-6 face-to-face meetings over 3-4 weeks, unlimited access to designated online resources.
Study NCT05703074 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Care as usual
Description: A brief self-help leaflet on long COVID is distributed, otherwise care as usual by the general practitioner
Study NCT05703074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: 4 capsules (empty) 2 times daily for 84 days.
Study NCT06111586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frexalimab
Description: Intravenous (IV) Infusion at Day 1 and subcutaneous (SC) Injection from W2 to W102
Study NCT06111586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Infusion at Day 1 and SC Injection from W2 to W102
Study NCT06111586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: SC injection, dose and frequency will be established and/or adjusted by investigator
Study NCT06111586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: SC injection, dose and frequency will be established and/or adjusted by investigator
Study NCT05144009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) Infusion
Study NCT05144009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cycle 1 - Intravenous (IV) Infusion. Cycle 2+ - Intravenous (IV) Infusion or Subcutaneous (SC) Administration.
Study NCT04772937 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: LLETZ
Description: LLETZ is one of several possible surgical interventions for treating cervical dysplasia. The transformation zone of the cervix is completely removed
Study NCT04772937 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: LEEP
Description: LEEP is one of several possible surgical interventions for treating cervical dysplasia. Only the dysplastic lesion is removed without removing the whole transformation zone.
Study NCT06015737 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).
Study NCT06015737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution for injection in aPFS.
Study NCT06485206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One level Mobi-C and one level fusion
Description: Cervical Disc Arthroplasty:~• Mobi-C~Fusion devices:~* One-level cervical plates~  o MaxAn Cervical plate system~* Interbody spacers~  * TrellOss-C - 3D printed Ti interbody~ * Vista-S - PEEK interbody~* Standalone Fixation~  * Ti-Coated ROI-C - PEEK cage w/ Ti coating~ * TrellOss-C SA - 3D printed Ti~* Bone Graft~  * Local Autograft~ * PrimaGen Advanced Allograft
Study NCT05092282 — intervention group
Intervention type: DEVICE
Intervention: Head and Intraocular Trauma Tool
Description: HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
Study NCT05554406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV